Articles

Poll

Podcasts

Slideshows

Videos

The FDA accepted Bayer’s sNDA for finerenone in adults with type 1 diabetes and CKD based on albuminuria data from FINE-ONE.

FDA Grants Priority Review to Finerenone for Type 1 Diabetes and CKD

 An expert describes his perspective on sequencing, APRIL inhibition, proteinuria endpoints, and long-term kidney preservation in IgA nephropathy.



APRIL Inhibition, Dual Blockade, and Proteinuria Endpoints in IgAN, With Edward Lerma, MD

On IgAN Awareness Day, clinicians highlight earlier diagnosis, dynamic risk stratification, and emerging targeted therapies reshaping care.

IgAN Enters “Mechanism-First Era” Reframing Diagnosis, Treatment, and Remission

Susztak, MD, PhD, offers insight into a new score that predicts which APOL1 carriers will actually develop kidney disease.

9-Protein Plasma Score Predicts Kidney Failure Risk in APOL1 High-Risk Individuals Before Visible CKD

Catch up on 5 nephrology headlines you missed in April 2026, including WCN coverage, FDA updates, and trial data. 

5 Nephrology Headlines You Missed in April 2026

APOL1 research is driving precision nephrology, but prediction gaps and equity challenges still limit clinical impact.

APOL1-Mediated Kidney Disease: From Genetic Discovery to the Edge of Precision Medicine

Garimella, MBBS, unpacks what clinicians need to know about APOL1-mediated kidney disease, including misclassification, testing barriers, and management gaps. 

Beyond Hypertensive Nephrosclerosis: A Closer Look at APOL1-Mediated Kidney Disease

Campbell answers questions about the current research and clinical landscape of APOL1-mediated kidney disease. 

APOL1 Reaches Turning Point While Clinical, Equity Challenges Persist, With Kirk Campbell, MD

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

The HCPFive: Top News for Healthcare Providers from the Week of 04/19

The FDA approved anifrolumab via a once-weekly subcutaneous autoinjector for moderate to severe SLE based on phase 3 TULIP-SC trial results.

Anifrolumab (Saphnelo) Wins FDA Approval for Subcutaneous Self-Administration in SLE

C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

Chronic Kidney Disease

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.